Search

Prostate cancer is the second most common cancer in American individuals with a prostate and the second leading cause of cancer death in the United States. Genome-wide association studies (GWAS) have identified more than 290 single nucleotide polymorphisms (SNPs) associated with prostate cancer. These SNPs can be combined to generate a Polygenic Risk Score (PRS), which estimates an individual’s risk to develop prostate cancer. To our knowledge, no other study has investigated the relationship between PRS and clinical factors in affected individuals, using a clinically ascertained population, while taking into account germline genetic testing in a known prostate-cancer related gene. A quantitative retrospective chart review of 175 individuals diagnosed with prostate cancer, received genetic counseling services at The Ohio State University’s Genitourinary Cancer Genetics Clinic, and received a PRS through Ambry Genetics, was performed. We found a statistically significant inverse relationship between PRS and age of diagnosis with individuals diagnosed less than 60 years of age being twice as likely to have a high PRS compared to individuals diagnosed over 60 years of age (p-value of 0.009). This supports the hypothesis that individuals diagnosed with prostate cancer at younger ages will have higher PRS and vice versa. We did not find a significant relationship between PRS and International Society of Urological Pathology Grade Group (ISUP GG), metastatic status, histology, or family history in a first or second-degree relative. However, larger population based studies are needed to understand the value of PRS in individuals with prostate cancer. Additionally, identifying individuals at higher risk for prostate cancer through PRS could allow for more personalized screening recommendations and potentially result in improved survival rates.